Clinical Trial Update: A Study of Nipocalimab or Intravenous Immunoglobulin (IVIG) in Pregnancies At Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT) [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial comparing Nipocalimab to intravenous immunoglobulin (IVIG) in pregnancies at risk for fetal and neonatal alloimmune thrombocytopenia is…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fetal and Neonatal Alloimmune Thrombocytopenia

Drugs mentioned

• Intravenous immunoglobulin (IVIG) (intravenous immunoglobulin)
• Nipocalimab (nipocalimab)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Thrombocytopenia, Neonatal Alloimmune | Phase 3 | Status: RECRUITING